secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001437749-24-031684
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar presents positive uPAR radiopharma dosimetry data at EANM 2024
----------------------------------------------------------------------

- MNPR-101-Lu shows favorable organ safety at high Lu-177 doses using human Zr-89 dosimetry data.
- Presentation accepted as 'Top-Rated Oral Presentation' at EANM 2024 in Hamburg, Germany.
- Preclinical and clinical data show favorable biodistribution, tumor uptake, and low off-target binding.
- MNPR-101-Lu ongoing Phase 1a trial (NCT06617169); MNPR-101-Zr imaging trial (NCT06337084).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924031684/0001437749-24-031684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924031684/mnpr20241021c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer